CTLA4 - cytotoxic T-lymphocyte associated protein 4 Gene
Also Known as CTLA-4
Species: Macaca mulatta
Gene Type: protein coding
Gene ID: 705673
About CTLA4
Primary_assembly 12: 91,268,710-91,274,863 forward strand.Mmul_10:CM014347.1
This gene has 1 transcript (splice variant), 157 orthologues and 1 paralogue.
CTLA4 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001044739.1 | NP_001038204.1 | cytotoxic T-lymphocyte protein 4 precursor |
CTLA4 Protein Structure
IgV_CTLA-4
IgV_CTLA-4: cd05721 (38 - 41)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (38 - 59)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (38 - 152)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (44 - 47)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (51 - 59)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (60 - 67)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (68 - 75)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (68 - 74)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (75 - 96)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (79 - 88)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (93 - 96)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (102 - 131)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (102 - 107)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (110 - 116)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (124 - 131)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (132 - 138)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (139 - 152)
IgV_CTLA-4
IgV_CTLA-4: cd05721 (139 - 151)
- 0
- 100
- 200
- 223 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
cytotoxic T-lymphocyte protein 4 |
|
Recombinant CTLA4 Proteins
| Art. -Nr. | Produktname | Accession | Reinheit |
|---|---|---|---|
| HY-P72958 | CTLA-4 Protein, Rhesus Macaque (HEK293, Fc) | Q9BDC4 (A37-D161) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P77345 | CTLA-4 Protein, Rhesus Macaque (HEK293, His) | Q9BDC4 (A37-D161) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Inhibitory Antibodies
(3)
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Rare Diseases
|
|---|---|---|---|---|
| HY-108829 | Abatacept | ≥99.0% | Unkown | |
| HY-P9901 | Ipilimumab | Inhibitor | 99.88% | Unkown |
| HY-P9918 | Tremelimumab | 99.50% | Unkown |
Clinical Phase
Inhibitory Antibodies
(24)
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Phase
|
|---|---|---|---|---|
| HY-P99540 | Tuvonralimab | Inhibitor | 99.14% | Phase 4 |
| HY-P99117 | Cadonilimab | Inhibitor | 99.87% | Phase 3 |
| HY-P990042 | Gotistobart | Inhibitor | ≥99.0% | Phase 3 |
| HY-P990690 | Volrustomig | Inhibitor | ≥99.0% | Phase 3 |
| HY-P99484 | Botensilimab | Inhibitor | 99.00% | Phase 3 |
| HY-P99166 | Vudalimab | Inhibitor | ≥99.0% | Phase 2 |
| HY-P99714 | Lorigerlimab | Inhibitor | 97.5% | Phase 2 |
| HY-P99514 | Zalifrelimab | Inhibitor | 98.28% | Phase 2 |
| HY-P990048 | Muzastotug | Inhibitor | 99.48% | Phase 2 |
| HY-P99809 | Quavonlimab | Inhibitor | ≥99.0% | Phase 2 |
| HY-P990080 | Sovipostobart | Inhibitor | 96.528% | Phase 2 |
| HY-P990739 | Evalstotug | 95.062% | Phase 2 | |
| HY-P990775 | Vilastobart | 99.63% | Phase 2 | |
| HY-P991566 | KD6001 | Inhibitor | / | Phase 2 |
| HY-P991960 | JS007 | / | Phase 2 | |
| HY-P990703 | Porustobart | 99.70% | Phase 1 | |
| HY-P99844 | Davoceticept | 99.9% | Phase 1 | |
| HY-P990041 | Firastotug | Inhibitor | 98.62% | Phase 1 |
| HY-P99709 | Lodapolimab | Inhibitor | 99.71% | Phase 1 |
| HY-P99760 | Nurulimab | Inhibitor | 95.00% | Phase 1 |
| HY-P99354 | Bavunalimab | 99.408% | Phase 1 | |
| HY-P991952 | ADU-1604 | Inhibitor | / | Phase 1 |
| HY-P991953 | BAT4706 | / | Phase 1 | |
| HY-P991961 | REGN4659 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(7)
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Rare Diseases
|
|---|---|---|---|---|
| HY-159692 | AZD8701 | Inhibitor | 96.61% | Unkown |
| HY-120120 | DZ-2384 | Inhibitor | / | Unkown |
| HY-122081 | CPI-644 | Inhibitor | / | Unkown |
| HY-RS03299 | CTLA4 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03300 | Ctla4 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03301 | Ctla4 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-179228 | AN02 | / | Unkown |
Inhibitory Antibodies
(17)
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99132 | Anti-Mouse CTLA-4 Antibody (9D9) | Inhibitor | 98.91% | Unkown |
| HY-108829A | Abatacept (powder) | Inhibitor | 99.01% | Unkown |
| HY-P990789 | Anti-Mouse CTLA-4 Antibody (9H10) | Inhibitor | 99% | Unkown |
| HY-P99943 | Erfonrilimab | 99.98% | Unkown | |
| HY-P990256 | Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) | Inhibitor | 98.68% | Unkown |
| HY-P990945 | Tazlestobart | 99.66% | Unkown | |
| HY-P990722 | Danvilostomig | 98.38% | Unkown | |
| HY-P991139 | Futermestotug | Inhibitor | 99.84% | Unkown |
| HY-P990848 | Anti-CTLA-4/CD152 Antibody (BN13) | Inhibitor | / | Unkown |
| HY-P991951 | ABA04 | / | Unkown | |
| HY-P991959 | JMW-3B3 | Inhibitor | / | Unkown |
| HY-P992062 | Anti-Mouse CD80 Antibody (TKMG48) | Agonist | / | Unkown |
| HY-P992177 | AI-025 | Inhibitor | / | Unkown |
| HY-P992511 | CS2009 | Inhibitor | / | Unkown |
| HY-P991775 | Anti-Rat CTLA-4 Antibody (WKH203) | Inhibitor | / | Unkown |
| HY-P991827 | Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) | Inhibitor | / | Unkown |
| HY-P991958 | GIGA-564 | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service